Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

by Hanker, Lars C. , Herzog, Thomas J. , Tian, Min , He, Zangdong , Boere, Ingrid , Copeland, Larry J. , Monk, Bradley J. , Buscema, Joseph , Coleman, Robert L. , Auranen, Annika , Zografos, Eleftherios , Chase, Dana M. , McCourt, Carolyn , dePont Christensen, René , Black, Destin , Powell, Matthew A. , Cibula, David , Landrum, Lisa M. , Stuckey, Ashley , Gilbert, Lucy , Stevens, Shadi , Shahin, Mark S. , Pothuri, Bhavana , Mirza, Mansoor R. , Raspagliesi, Francesco , Sharma, Sudarshan , Slomovitz, Brian M. , Gold, Michael A. , Gill, Sarah E. , Valabrega, Giorgio , Novák, Zoltán

in Adverse events / Antibodies, Monoclonal, Humanized / Antibodies, Monoclonal, Humanized - administration & dosage / Antibodies, Monoclonal, Humanized - adverse effects / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Antineoplastic Combined Chemotherapy Protocols - therapeutic use / Apoptosis / Cancer / Cancer therapies / Carboplatin / Carboplatin - administration & dosage / Carboplatin - adverse effects / Cell death / Chemotherapy / Cytotoxicity / DNA Mismatch Repair / dostarlimab / Double-Blind Method / Endometrial cancer / Endometrial Neoplasms - drug therapy / Endometrial Neoplasms - genetics / Endometrial Neoplasms - mortality / Endometrial Neoplasms - pathology / Endometrium / Female / General Medicine / Gynecologic Oncology / Gynecology / Hematology / Hematology/Oncology / Human health sciences / Humans / Hypothesis testing / Immune Checkpoint Inhibitors / Immune Checkpoint Inhibitors - administration & dosage / Immune Checkpoint Inhibitors - adverse effects / Immunotherapy / Medicine (all) / Microsatellite Instability / Mismatch repair / Monoclonal antibodies / Neoplasm Recurrence, Local - drug therapy / Neoplasm Recurrence, Local - etiology / Obstetrics / Obstetrics/Gynecology / Oncologie / Oncology / Paclitaxel / Paclitaxel - administration & dosage / Paclitaxel - adverse effects / Placebos / Quality of life / Questionnaires / Sciences de la santé humaine / Solid tumors / Statistical analysis / Targeted cancer therapy / Treatments in Oncology / Tumors

2023

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

2023

Confirm

Do you wish to request the book?

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

2023

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

Hanker, Lars C.,

Herzog, Thomas J.,

Tian, Min,

He, Zangdong,

Boere, Ingrid,

Copeland, Larry J.,

Monk, Bradley J.,

Buscema, Joseph,

Coleman, Robert L.,

Auranen, Annika,

Zografos, Eleftherios,

Chase, Dana M.,

McCourt, Carolyn,

dePont Christensen, René,

Black, Destin,

Powell, Matthew A.,

Cibula, David,

Landrum, Lisa M.,

Stuckey, Ashley,

Gilbert, Lucy,

Stevens, Shadi,

Shahin, Mark S.,

Pothuri, Bhavana,

Mirza, Mansoor R.,

Raspagliesi, Francesco,

Sharma, Sudarshan,

Slomovitz, Brian M.,

Gold, Michael A.,

Gill, Sarah E.,

Valabrega, Giorgio,

Novák, Zoltán

2023

Overview

A randomized trial compared standard chemotherapy plus dostarlimab or placebo. Patients with mismatch repair–deficient tumors had 2-year progression-free survival of 61.4% with dostarlimab and 15.7% with placebo.

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society,Massachussetts Medical Society

Subject

Adverse events

/ Antibodies, Monoclonal, Humanized

/ Antibodies, Monoclonal, Humanized - administration & dosage

/ Antibodies, Monoclonal, Humanized - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - adverse effects

/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use

/ Apoptosis